Prognostic Factors and Survival in Surgically Treated Stage III Non-Small Cell Lung Cancer: A Real-World Single-Center Retrospective Cohort Study
Current Oncology · 28.05.2026 · 33 (6) · 316
DOI: 10.3390/curroncol33060316 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Current Oncology, online erschienen am 28.05.2026. Verfasst von Bekir Elma und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, Faculty of Medicine, Gaziantep University, 27310 Gaziantep, Türkiye. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Stage III non-small cell lung cancer (NSCLC) represents a clinically and biologically heterogeneous disease group, posing challenges in treatment standardization.
Objective
This study aimed to evaluate survival outcomes and prognostic factors in patients with pathological stage III NSCLC undergoing upfront surgery in a real-world setting.
Methods
Patients treated between January 2009 and December 2023 were retrospectively analyzed. All patients underwent anatomical resection with systematic mediastinal lymph node dissection and achieved complete (R0) resection. Overall survival (OS) and recurrence-free survival (RFS) were estimated using the Kaplan–Meier method, and prognostic factors were evaluated using Cox proportional hazards regression. Nomograms were developed for individualized survival prediction.
Results
A total of 390 patients were included, with a median follow-up of 35 months. The median OS was 47 months, and the median RFS was 30 months. Multivariable analysis identified age, PET-detected mediastinal nodal involvement, tumor location, postoperative complications, pathological nodal status, adjuvant chemotherapy, and adjuvant radiotherapy as independent predictors of OS (p = 0.001, p = 0.029, p = 0.006, p =0.002, p = 0.009, and 0.004, respectively), while adjuvant chemotherapy was associated with improved survival (p = 0.010). For RFS, pathological N2b disease, stage IIIB, tumor location, and adenocarcinoma histology were independent predictors (p = 0.001, p = 0.016, p = 0.029, and p = 0.027, respectively). The OS nomogram demonstrated moderate discriminative ability, whereas the RFS model showed limited predictive performance.
Conclusions
These findings highlight the substantial heterogeneity of stage III NSCLC and emphasize the importance of individualized, multidisciplinary treatment strategies beyond conventional staging systems.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Thoracic Surgery, Faculty of Medicine, Gaziantep University, 27310 Gaziantep, Türkiye.
- Department of Thoracic Surgery, Alanya Training and Research Hospital, 07400 Antalya, Türkiye.
- Department of Biostatistics, Faculty of Medicine, Gaziantep University, 27310 Gaziantep, Türkiye.
ORCID-Profile: Bekir Elma, Ahmet Ferudun Isik
Zitieren
APA
Elma, B., Kumbasar, H. Z., Dogan, I., Ulusan, A., Sanli, M., & Isik, A. F. (2026). Prognostic Factors and Survival in Surgically Treated Stage III Non-Small Cell Lung Cancer: A Real-World Single-Center Retrospective Cohort Study. Current Oncology, 33(6), 316. https://doi.org/10.3390/curroncol33060316
Vancouver
Elma B, Kumbasar HZ, Dogan I, Ulusan A, Sanli M, Isik AF. Prognostic Factors and Survival in Surgically Treated Stage III Non-Small Cell Lung Cancer: A Real-World Single-Center Retrospective Cohort Study. Current Oncology. 2026;33(6):316. doi:10.3390/curroncol33060316
BibTeX
@article{Elma2026,
author = {Elma, Bekir and Kumbasar, Hilal Zehra and Dogan, Ilkay and Ulusan, Ahmet and Sanli, Maruf and Isik, Ahmet Ferudun},
title = {Prognostic Factors and Survival in Surgically Treated Stage III Non-Small Cell Lung Cancer: A Real-World Single-Center Retrospective Cohort Study},
journal = {Current Oncology},
year = {2026},
volume = {33},
number = {6},
pages = {316},
doi = {10.3390/curroncol33060316}
}
EUVIMED